HC Wainwright Has Strong Estimate for TCRX FY2025 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Research analysts at HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for shares of TScan Therapeutics in a note issued to investors on Thursday, November 13th. HC Wainwright analyst A. Maldonado now anticipates that the company will post earnings of ($1.05) per share for the year, up from their prior forecast of ($1.17). HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.12) per share. HC Wainwright also issued estimates for TScan Therapeutics’ Q4 2025 earnings at ($0.23) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.22) EPS, Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($0.88) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.80) EPS and FY2029 earnings at ($0.47) EPS.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.07. The firm had revenue of $2.51 million for the quarter, compared to analysts’ expectations of $1.98 million. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 73.33%.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley downgraded shares of TScan Therapeutics from an “overweight” rating to an “equal weight” rating in a research report on Friday, November 14th. BTIG Research cut TScan Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday, November 4th. Needham & Company LLC cut their price target on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Wednesday, October 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $7.00 price objective on shares of TScan Therapeutics in a research note on Tuesday, August 12th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $6.60.

TScan Therapeutics Stock Up 2.1%

Shares of TCRX stock opened at $0.99 on Monday. The company has a current ratio of 6.44, a quick ratio of 6.44 and a debt-to-equity ratio of 0.23. TScan Therapeutics has a 12 month low of $0.96 and a 12 month high of $4.94. The stock has a market cap of $56.19 million, a P/E ratio of -0.88 and a beta of 1.00. The company has a 50 day simple moving average of $1.80 and a two-hundred day simple moving average of $1.69.

Institutional Investors Weigh In On TScan Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Letko Brosseau & Associates Inc. lifted its position in shares of TScan Therapeutics by 113.0% in the first quarter. Letko Brosseau & Associates Inc. now owns 77,100 shares of the company’s stock valued at $106,000 after acquiring an additional 40,900 shares in the last quarter. Deutsche Bank AG raised its position in shares of TScan Therapeutics by 149.4% during the first quarter. Deutsche Bank AG now owns 52,559 shares of the company’s stock valued at $73,000 after buying an additional 31,481 shares during the last quarter. Nuveen LLC purchased a new position in TScan Therapeutics during the first quarter valued at $97,000. Aberdeen Group plc increased its holdings in TScan Therapeutics by 0.9% in the 1st quarter. Aberdeen Group plc now owns 891,448 shares of the company’s stock valued at $1,230,000 after acquiring an additional 7,744 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in TScan Therapeutics in the 1st quarter valued at $49,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.